NCT03598166View on ClinicalTrials.gov

Assessing the Effect of a Blood-based Colorectal Cancer Screening Test on Screening Adherence and Colonoscopy Completion

NACompletedINTERVENTIONAL

Enrollment

359

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions

Colorectal Cancer

Interventions

DIAGNOSTIC_TEST

Septin9

Septin9 is a FDA-approved blood test for colorectal cancer screening

Trial Locations (1)

10128

VA New York Harbor Health Care System, New York

All Listed Sponsors

lead

Peter S. Liang, MD MPH

FED

NCT03598166 - Assessing the Effect of a Blood-based Colorectal Cancer Screening Test on Screening Adherence and Colonoscopy Completion | Biotech Hunter | Biotech Hunter